Where does Janssen BioPharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Janssen BioPharma, Inc. ranks #14,705 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Janssen BioPharma, Inc. hold?

Janssen BioPharma, Inc. holds 20 US utility patents granted between 2019 and 2025, spanning 13 technology areas.

What is Janssen BioPharma, Inc.'s Innovation Score?

Janssen BioPharma, Inc. has an Innovation Score of 36.4 out of 100 (top 46% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Janssen BioPharma, Inc. focus on?

Janssen BioPharma, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 16 patents, ranking #1,230 of 6,058 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Is Janssen BioPharma, Inc.'s patent grant rate increasing or decreasing?

Janssen BioPharma, Inc.'s recent grant velocity is +750% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Janssen BioPharma, Inc.'s patents?

Janssen BioPharma, Inc.'s patents average 20.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Janssen BioPharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Janssen BioPharma, Inc.

USPTO PatentsView assignee record - 20 granted patents across 13 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Janssen ranks #14,705 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 13 technology areas.

#14,705
of 49,997 US assignees by volume: Top 46%
by Innovation Score (36.4/100): 20.6
avg claims per patent: +750%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14705 · US Corporation #14,705 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 20 grants
MID-PACK #14,705/49,997
PHOTO-FINISH Jingning Meige…
CPC-FOCUS A61P · 13 areas
INNOV-THIN 36.4/100
CLAIMS-DENSE 20.6 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +750% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Jingning Meige Technology Service Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Janssen’s 36.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.5 pts (29%) Velocity 0.8 pts (2%) Breadth 12.7 pts (35%) Claim depth 12.4 pts (34%)

Qualcomm Incorporated · highest

85
Janssen BioPharma · this assignee

36
3D Lighting… · lowest

7

What this shows Janssen's Innovation Score is 36.4/100 (top 46% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Janssen?

Each dot is one of Janssen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Janssen’s own 20.6 claims/patent is ABOVE the 17.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Janssen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Janssen's grants concentrate

Janssen BioPharma, Inc. is a focused PatentsView assignee: 13 CPC subclasses with 80% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (8 grants) versus a trough of 1 in 2022. By volume, Janssen sits between Jingning Meige Technology Service Co., Ltd. and Kajeet, Inc..

Janssen's three-year grant acceleration

Janssen BioPharma, Inc. shows 2 grants in 2022–2024 against only 17 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Jingning Meige Te…

20
Jmea

20
Jost-werke Deutsc…

20
JST Power Equipme…

20
Johnson Controls…

20
Jubilant Draximage

20
Just Fur Love

20
Kajeet

20
Janssen Biopharma ◀

20

What this shows Janssen holds 20 patents at rank #14,707, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Janssen

By rank, the assignees closest to #14,707 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Janssen's primary technology class.

Janssen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 46% higher than 54% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Janssen BioPharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	10.0%
2020	8	40.0%
2021	7	35.0%
2022	1	5.0%
2024	1	5.0%
2025partial year	1	5.0%

Which technologies does Janssen BioPharma, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 16

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 11

C07D - Heterocyclic Compounds 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07C - Acyclic OR Carbocyclic Compounds 1

C12Y - Enzymes 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Janssen BioPharma, Inc.'s patent record in context - here's where to go next.

Janssen BioPharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #14,705 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Janssen BioPharma, Inc. against Jingning Meige Technology Service Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.